Bristol Myers Squibb Says Phase 3 IPF Trial Met Primary Endpoint
Bristol Myers Squibb said its Phase 3 ALOFT-IPF trial evaluating admilparant in adults with idiopathic pulmonary fibrosis met its primary endpoint.
Story updates
10:52:59 AM UTC
SquawkNews
BMY Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint
11:12:27 AM UTC
SquawkNews
Bristol Myers Squibb NYSE:BMY said on Monday a lower dose of its experimental drug met the main goal of a late-stage trial in patients with idiopathic pulmonary fibrosis, a serious lung-scarring disease.Shares of the company were up over 6% in premarket trading.The trial, which enrolled 1,255 peopl…